New nasal NO (nNO) application with NIOX VERO®

nNO is a sensitive and specific marker for Primary Ciliary Dyskinesia (PCD)

Diagnosis of PCD is often delayed or missed completely

One study reported that 70% of patients had over 50 appointments before diagnosis was made.

What is the role of nasal Nitric Oxide (nNO)?

- nNO has been shown to be decreased in patients with PCD.
- Measurement of nNO can assist in the identification of cases of PCD according to ERS guidelines.
- Effective screening of patients with low risk can rule out non PCD cases and avoid further invasive and expensive confirmatory tests, whilst not missing true cases.

The only CE marked nNO device with documented clinical data for differentiating patients with PCD from healthy individuals
NIOX VERO® nNO application provides a non-invasive and cost-efficient way to differentiate patients with PCD from healthy individuals.

- In a multi-centre, non-randomised study of 152 subjects ≥5 years with known PCD (47) vs. age matched healthy controls (105), NIOX VERO nNO was shown to be an effective screening tool between the two groups.
- Subjects completed at least two successful nNO measurements from one nostril using either passive tidal breathing sampling method (TB-nNO) or expiration against resistance method (ER-nNO).
- The obtained cut-off values demonstrated that both TB-nNO (171 ppb) and ER-nNO (356 ppb) methods in NIOX VERO can be used in children and adult patients as part of the diagnostic work-up of PCD.

NIOX VERO is the only CE marked nNO device supported with clinical evidence that delivers the following:

- The only fully portable device for nNO measurement
- Ease of use
- Patient facing display
- Two options for measuring, either tidal measurement or during exhalation against a resistor
- 30 second aspiration time
- The only CE marked nNO device with documented clinical data for differentiating patients with PCD from healthy individuals

NIOX VERO®

NIOX VERO quantitatively measures Nitric Oxide in human breath (Fractional exhaled Nitric Oxide, FeNO) and nasal Nitric Oxide (nNO) in the aspirated air from the nasal cavity. nNO - Nasal Nitric Oxide has been shown to be decreased in patients with Primary Ciliary Dyskinesia (PCD), and measurement of nNO can assist in the identification of cases of PCD according to ERS guidelines. Measurement of nNO with the NIOX VERO Nasal Measurement Mode is non-invasive, simple, safe and repeatable in patients age 5 and above when measured according to the NIOX VERO Nasal Measurement Mode User Manual. Suspected cases of PCD following screening with nNO should be confirmed according to published recommendations for PCD diagnosis and management.

REFERENCES:
4. *Fractional exhaled nitric oxide

Contact your local representative.
Visit niox.com for more information.